Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca/Cellartis To Use Human Embryonic Stem Cells For Predictive Toxicology

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. firm looks to increase safety, avoid expensive late-stage failures with preclinical screening on real human liver and heart muscle tissue.

You may also be interested in...



France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies

The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.

France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies

The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.

iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform

Every so often an undeniably important technology emerges resulting in the consolidation of IP and the alignment of thought leaders around a few main players. The new battleground is stem cells. And though the two heavy hitters in the promising induced pluripotent stem (iPS) cell space, Ipierian and Fate Therapeutics, are perhaps less aggressive in publicly asserting their dominance, they've positioned themselves as leading competitors in the still-nascent but rapidly advancing area of cellular reprogramming.

Topics

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel